SEARCH

Current Edition

Johnson & Johnson

Pressed by Wall Street, pharma executives signal openness to M&A

Pharmaceutical executives are getting asked the same question. With many large drugmakers flush with cash, and valuations of publicly traded biotech companies crashing, analysts on …

Continue Reading →
Astellas

Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst

The $62 billion Takeda-Shire deal surprised everyone—and worries some—as Takeda is borrowing an enormous $31 billion to help pay for the purchase. Does it refresh the …

Continue Reading →